Ipsen presents studies highlighting new approaches for severe cancers
Category: #health  By Pankaj Singh  Date: 2019-09-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ipsen presents studies highlighting new approaches for severe cancers

Today, people across the world are prone to numerous health disorders, and cancer is one of the major diseases which is growing at an alarming rate. Researchers around the world are putting their best foot forward to develop new therapies and next-generation treatment for targeting serious disease such as cancer. Advancements through clinical trials towards cancer treatment can improve existing or introduce novel treatments pathways.

Ipsen is one such company which reportedly announced that the company will be presenting information regarding the clinical trial of cabozantinib (Cabometyx®) for treatment of a variety of tumor types at the European Society for Medical Oncology (ESMO) Congress 2019, being conducted in Barcelona, Spain, from 27 September to 1 October 2019.

According to the sources, through this presentation, the company will be demonstrating promising advances for advanced neuroendocrine tumors, hepatocellular carcinoma, and metastatic pancreatic cancer.

Dr. Alexandre Lebeaut, Ipsen’s Executive Vice President, R&D and Chief Scientific Officer stated that the company’s mission is to accelerate the development, discovery, and commercialization of novel medicines for the treatment of the disease. The company will be presenting new studies at ESMO regarding the treatment of difficult-to-treat cancer so that no one should be left behind.

Below are the key studies that the company will be presenting at ESMO 2019 Congress:

  • A summary of trial design of its pivotal Phase III (COSMIC-312) trial that assesses cabozantinib in combination with atezolizumab against sorafenib in patients who are suffering from advanced hepatocellular carcinoma (aHCC) and have received no systemic anticancer therapy previously.

 

  • New QTWiST study analysis of the Phase III CELESTIAL by observing second line cabozantinib’s effect on patients’ health who are suffering from aHCC after sorafenib.

Bartek Bednarz, Ipsen, Senior Vice-President, Oncology Franchise said that along with the company’s research programs for difficult to treat cancer like pancreatic adenocarcinoma and lung cancer, the company’s additional work is also creating new approaches in treatment for patients that have substantial unmet needs.

Bednarz further said that ESMO 2019 is a vital milestone for the company’s collaboration with Exelixis to develop cabozantinib further. The company has exceeded 100 joint abstracts regarding cabozantinib that have been accepted to the medical congresses for the treatment of difficult-to-treat cancers.

 

Source Credit - https://www.ipsen.com/press-releases/ipsen-showcases-studies-at-the-esmo-2019-congress-highlighting-progress-in-new-approaches-for-difficult-to-treat-cancers/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

CoSara receives Indian regulatory authorization for its five IVDs
CoSara receives Indian regulatory authorization for its five IVDs
By Pankaj Singh

Co-Diagnostics, a renowned US-based molecular diagnostics company, having a patented, unique platform to develop diagnostics tests reportedly announced that CoSara Diagnostics, the company’s JV for production, has received regulatory clearance ...

U.S. government could issue new rules to block shipments to Huawei
U.S. government could issue new rules to block shipments to Huawei
By Pankaj Singh

  Trump administration had issued 75 licenses to allow Huawei suppliers to resume sales U.S. Commerce Department and other authorities focused on utilizing De minimis Rule The U.S. government is reportedly considering new policies to restr...

Cinda finalizes Phase I study of anti-PD-1 / HER2 bispecific antibody
Cinda finalizes Phase I study of anti-PD-1 / HER2 bispecific antibody
By Pankaj Singh

Cinda Biopharmaceutical, a startup that focuses on treating autoimmune and metabolic diseases, has recently announced the completion of its Phase I clinical study of human epidermal growth factor receptor-2 (HER2) and antibodies against programmed de...